Contrast-induced nephropathy: current practices among cardiologists

REFERENCES

• Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: A consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–1613.
   PubMed Web of Science ®Google Scholar
• Thomsen H, Morcos S. Contrast media and the kidney: European Society of Urogenital Radiololgy (ESUR) guidelines. Br J Radiol. 2003;76:513–518.
   PubMed Web of Science ®Google Scholar
• Rihal CS, Textor SC, Grill DE. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259–2264.
   PubMed Web of Science ®Google Scholar
• McCullough P, Wolyn R, Rocher L, Acute renal failure after PCI: Incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–375.
   PubMed Web of Science ®Google Scholar
• Gruberg L, Mintz GS, Mehran R, The prognostic implications of further renal function deterioration within 48 hrs of interventional coronary procedures in prospective trial. Ann Intern Med. 1989;110:119–124.
   PubMedGoogle Scholar
• Michael R, Harold F. Contrast induced nephropathy: What are the true clinical consequences. Clin J Am Soc Nephrol. 2008;3(1):263–272.
   PubMed Web of Science ®Google Scholar
• Schweiger M, Chambers C, Davidson C, Prevention of contrast induced nephropathy: Recommendations for the high risk patient undergoing cardiovascular procedures. Catheterization Cardiovasc Interven. 2007;69:135–140.
   PubMed Web of Science ®Google Scholar
• Benko A, Fraser-Hill M, Magner P Capusten B, Canadian association of radiologists: Consensus guideline for the prevention of contrast induced nephropathy. CARJ. 2007;58(2):79–87.
   Google Scholar
• Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: Specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84(2):170–179.
   PubMed Web of Science ®Google Scholar
• Solomon R, Deray G. Consensus Panel for CIN How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations. Kidney Int Suppl. 2006;100:S51–S53.
   Google Scholar
• Kakkar R, Sobieszczyk P, Binkert CA, Faxon DP, Mortele KJ, Singh AK. Prevention of intravenous contrast-induced nephropathy in hospital. Crit Pathw Cardiol. 2008;7(1):1–4.
   PubMedGoogle Scholar
• National Kidney Foundation DOQI. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Available at: http://www.kidney.org/professionals/KDOQI/guidelines_cvd/guide2.htm. Accessed July 7.
   Google Scholar
• King SB III, Smith SC J, Hirshfeld JW Jr, 2007. Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117(2):261–295. Epub 2007 Dec 13.
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith SC Jr, 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205–2241.
   PubMed Web of Science ®Google Scholar
• Rudnick MR, Goldfarb S, Wexler L, Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47(1):254–261.
   PubMed Web of Science ®Google Scholar
• Davidson CJ, Hlatky M, Morris KG, Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med. 1989;110(2):119–124.
   PubMed Web of Science ®Google Scholar
• Lautin EM, Freeman NJ, Schoenfeld AH, Radiocontrast-associated renal dysfunction: Incidence and risk factors. AJR Am J Roentgenol. 1991;157(1):49–58.
   PubMed Web of Science ®Google Scholar
• Levey AS; Atkins R; Coresh J, Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–259. Epub 2007 Jun 13.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17):2154–2169.
   PubMed Web of Science ®Google Scholar
• Brosius FC 3rd, Hostetter TH, Kelepouris E, Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in collaboration with the National Kidney Foundation. Circulation. 2006;114(10):1083–1087. Epub 2006 Aug 7.
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl. 1):S1–S266.
   PubMed Web of Science ®Google Scholar
• Anavekar NS, McMurray JJ, Velazquez EJ, Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction [published comments in ACP J Club. 2005;142:51, N Engl J Med. 2004;351:1344–1346, and N Engl J Med. 2005;352:199–200; author reply 199–200]. N Engl J Med. 2004;351:1285–1295.
   PubMedGoogle Scholar
• Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: The Steno hypothesis [published comment in Diabetologia. 1989;32:766–767]. Diabetologia. 1989;32:219–226.
   PubMed Web of Science ®Google Scholar
• Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103(14):1869–1874.
   PubMed Web of Science ®Google Scholar
• Molitoris BA, Levin A, Warnock DG, Improving outcomes of acute kidney injury: Report of an initiative. Nat Clin Pract Nephrol. 2007;3(8):439–442.
   PubMedGoogle Scholar
• Lameire N, Adam A, Becker CR, Baseline renal function screening. Am J Cardiol. 2006;198(6A):21K–26K. Epub 2006 Feb 20.
   Google Scholar
• McCullough PA, Sandberg KR. Epidemiology of contrast induced nephropathy. Rev Cardiovasc Med. 2003;4(Suppl. 5):S3–S9.
   Google Scholar
• Jo SH, Youn TJ, Koo BK, Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study: A randomized controlled trial. J Am Coll Cardiol. 2006;48(5):924–930. Epub 2006 Aug 17.
   PubMed Web of Science ®Google Scholar
• McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48(4):692–699. Epub 2006 Jul 24.
   PubMed Web of Science ®Google Scholar
• Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: A meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2009;2(7):645–654.
   PubMed Web of Science ®Google Scholar
• Thomsen HS, Morcos SK, Erley CM, The ACTIVE Trial: Comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43(3):170–178.
   PubMed Web of Science ®Google Scholar